@article{f92bb80718684a5ca9feeb76212f413c,
title = "Impact of the COVID-19 pandemic on people living with migraine: Results of the MiCOAS qualitative study",
abstract = "Background: The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global health crisis that has had a range of impacts on people living with migraine. Methods: Qualitative interviews performed as part of the Migraine Clinical Outcome Assessment System project, a multi-stage Food and Drug Administration–grant funded program to develop a patient-centered core set of outcome measures for use in migraine clinical trials, offered an opportunity to explore the experience of living with migraine during the pandemic as well as to examine whether migraine treatment priorities, symptoms, and associated disability changed due to the pandemic. Semi-structured interviews were conducted in the United States between the summer and fall of 2020 with 40 individuals with self-reported, medically diagnosed migraine who self-reported that they had not tested positive for or been diagnosed with COVID-19. Results: Seventy percent (n = 28) of the sample reported ≥1 pandemic-related impact on their life with migraine. Fourteen participants reported both positive and negative impacts, twelve reported negative impacts only, and two reported positive impacts only. Among those reporting ≥1 pandemic-related impact, nine participants (32%) reported more frequent and five (17%) reported less frequent migraine attacks. Other negative impacts included interrupted medical care (n = 9; 32%), and greater stress (n = 13; 46%). The most frequent positive impact reported was greater access to health care (n = 8; 29%). Ictal and interictal symptoms were not noted to change due to the pandemic, but some respondents reported less disability due to increased flexibility of schedules and reduced expectations. Treatment priorities did not change due to the pandemic. Conclusion: The global COVID-19 pandemic has resulted in both negative and positive impacts for people living with migraine. Lessons to be considered when moving into a post-pandemic world include benefits of and satisfaction with telehealth and the benefits and importance of healthy lifestyle habits and flexibility such as improved sleep, reduced stress, and fewer social expectations.",
keywords = "Food and Drug Administration, coronavirus disease 2019 (COVID-19), impact, migraine, pandemic, qualitative",
author = "Buse, {Dawn C.} and Gerstein, {Maya T.} and Houts, {Carrie R.} and McGinley, {James S.} and Uzumcu, {Alyssa A.} and McCarrier, {Kelly P.} and Alexis Cooke and Touba, {Nancy M.} and Nishida, {Tracy K.} and Wirth, {R. J.} and Lipton, {Richard B.}",
note = "Funding Information: This manuscript was supported by the Food and Drug Administration (FDA) of the US Department of Health and Human Services (HHS) as part of a financial assistance award (UH3FD006795) totaling $1,599,834 with 100 percent funded by FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the US Government Funding Information: This manuscript was supported by the Food and Drug Administration (FDA) of the US Department of Health and Human Services (HHS) as part of a financial assistance award (UH3FD006795) totaling $1,599,834 with 100 percent funded by FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the US Government The authors would like to thank the US Food and Drug Administration including Robyn Bent, MS; the Coalition for Headache and Migraine Patients (CHAMP) for assisting in recruitment; and David W. Dodick, MD, Walter F. Stewart, PhD, MPH, Elizabeth Nicki Bush, MHS, Roger Cady, MD, Katie M. Golden, BA, Peter Goadsby, MD, PhD, and Rikki Mangrum, MLS. Funding Information: Dawn C. Buse is a part‐time employee of Vector Psychometric Group LLC, which in turn received funds from the FDA to conduct the research detailed in the manuscript. In addition, she receives research funding from the National Headache Foundation and Amgen. She has been a consultant to Allergan/Abbvie, Amgen, Lilly, Lundbeck, and Teva Pharmaceuticals. Maya T. Gerstein was a full‐time employee of Pharmerit/OPEN Health, which in turn received funds from Vector Psychometric Group LLC and the FDA to conduct the research detailed in the manuscript. Carrie R. Houts is a full‐time employee of Vector Psychometric Group LLC, which in turn received funds from the FDA to conduct the research detailed in the manuscript. James S. McGinley is a full‐time employee of Vector Psychometric Group LLC, which in turn received funds from the FDA to conduct the research detailed in the manuscript. JSM has received honoraria/payment/reimbursement from the journal Cephalalgia (biostatistics editor). JSM has also received research grants/support from Amgen, Inc. and the National Headache Foundation. Alyssa A. Uzumcu was a full‐time employee of Pharmerit/OPEN Health, which in turn received funds from Vector Psychometric Group LLC and the FDA to conduct the research detailed in the manuscript. Kelly P. McCarrier is a full‐time employee of Pharmerit/OPEN Health, which in turn received funds from Vector Psychometric Group LLC and the FDA to conduct the research detailed in the manuscript. Alexis Cooke was a full‐time employee of Pharmerit/OPEN Health, which in turn received funds from Vector Psychometric Group LLC and the FDA to conduct the research detailed in the manuscript. Nancy M. Touba is a full‐time employee of Pharmerit/OPEN Health, which in turn received funds from Vector Psychometric Group LLC and the FDA to conduct the research detailed in the manuscript. Tracy K. Nishida is a full‐time employee of Vector Psychometric Group LLC, which in turn received funds from the FDA to conduct the research detailed in the manuscript. R. J. Wirth is a full‐time employee of Vector Psychometric Group LLC, which in turn received funds from the FDA to conduct the research detailed in the manuscript. Richard B. Lipton received research support from the FDA on the MiCOAS project. In addition, he receives research funding from the NIH, the National Headache Foundation, and the Marx Foundation. He also receives research support from Allergan/Abbvie, Amgen, Biohaven, Eli Lilly, and Electrocore. He receives personal fees as a consultant or advisor from Allergan/Abbvie, Amgen, Biohaven Holdings, Dr. Reddy{\textquoteright}s, GlaxoSmithKline, Grifols, Eli Lilly, Lundbeck, Merck, Novartis, and Teva Pharmaceuticals. He holds stock or options in Biohaven Holdings and CtrlM Health. In addition, he receives royalties for , 7th and 8th editions. Wolff{\textquoteright}s Headache Publisher Copyright: {\textcopyright} 2022 American Headache Society.",
year = "2022",
month = mar,
doi = "10.1111/head.14274",
language = "English (US)",
volume = "62",
pages = "284--293",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "3",
}
